Privia Health (NASDAQ:PRVA) just turned in a quarter that checked every box management set for itself, and then raised the bar again for the rest of the year. On the company’s August 6 earnings call, CEO Parth Mehrotra and CFO David Mountcastle laid out a business adding doctors, patients, and cash at a pace that has held for nine straight years. The question is whether the market is pricing in the streak continuing.
Table of Contents
Bull Case: A Growth Engine Still Humming
Privia’s numbers move together. Implemented providers grew 10.1% year-over-year to 5,644, adding 109 physicians in the quarter alone, while value-based attributed lives climbed 19.2%. That combination pushed practice collections up 12.4% to $970 million in the second quarter and 13.4% to $1.88 billion for the first half. Adjusted EBITDA rose 29% to $37.4 million, with margin as a share of care margin expanding 310 basis points to 28.3%, a sign the business is getting more profitable as it scales, not just bigger.
In late May, Privia entered New Jersey, its 25th state, through a partnership with the Urology Group of Bergen County covering 25 clinicians. Commercial attributed lives rose 11.7% to 942,000, while CMS Medicare lives jumped 55%. The company now oversees an estimated $15.7 billion in total medical spend across more than 130 value-based programs, and gross provider retention has averaged 98% over the past three years. Management raised 2026 guidance across practice collections, care margin, GAAP revenue, platform contribution, and EBITDA, with attributed lives already tracking above the prior high end.
Bear Case: Cash Timing And Policy Are Wildcards
The growth story comes with a few strings attached. Privia became a full cash taxpayer this year, and management expects only 70% to 80% of full-year adjusted EBITDA to convert to free cash flow, a figure that assumes the company collects a significant chunk of its 2025 shared savings payments by year-end. That assumption now has a complication: CMS proposed changes to the Medicare Shared Savings Program for performance year 2025 that could delay final reconciliation results until November, which management says could create an atypical year-end cash flow pattern even though the accrual impact looks minimal.
The company also holds $412 million in cash with no debt, which is a comfortable cushion, but its raised guidance still assumes no additional business development activity, meaning any acquisitions would be upside not yet baked in.
